 CANTON, Mass., Nov. 13, 2020 GLOBE NEWSWIRE -- Organogenesis Holdings Inc. Nasdaq: ORGO, a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical Sports Medicine markets, today announced the pricing of an underwritten public offering of 17,500,000 shares of its Class A common stock, offered at a price to the public of 3.25 per share. The gross proceeds to Organogenesis Holdings from this offering are expected to be approximately 56.9 million, before deducting the underwriting discounts and commissions and other offering expenses payable by Organogenesis Holdings. Organogenesis Holdings has granted the underwriters a 30-day option to purchase up to an aggregate of 2,625,000 additional shares of its Class A common stock. The offering is expected to close on or about November 17, 2020, subject to customary closing conditions. 